Equations are changing in Indian pharmaceutical houses like never before especially after closing down or waning of much-talked about reverse engineering in biggest democracy of the world. Being a signatory country in GATT, India is bound to follow rules in treaty. Pipeline may yield some fruitful drug candidates in coming years, but so far drug discovery scenario in India is not commendable. Recently, using compulsory license provision, Hyderabad based Natco pharma got success in launching generic version of Nexavar (Nexavar is manufactured by Bayer HealthCare AG, Leverkusen, Germany for Bayer Pharmaceuticals Corporation, West Haven, Conn. and by Onyx Pharmaceuticals, Inc., Emeryville, California) and made history by becoming the first pharma industry in India to make use of compulsory license by state intervention. This article will take reader through various provisions of compulsory license, legal battle besides ramification of this ruling of Indian court in the favour of Natco pharma.
Loading....